DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

32.30B

Market cap32.30B

Price-Earnings ratio

34.04

Price-Earnings ratio34.04

Dividend yield

—

Dividend yield—

Average volume

4.61M

Average volume4.61M

High today

$86.61

High today$86.61

Low today

$85.12

Low today$85.12

Open price

$86.32

Open price$86.32

Volume

591.06K

Volume591.06K

52 Week high

$92.59

52 Week high$92.59

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $85.61. The company's market cap stands at 32.3B, with a P/E ratio of 34.04.

On 2026-10-02, DexCom(DXCM) stock traded between a low of $85.12 and a high of $86.61. Shares are currently priced at $85.61, which is +0.6% above the low and -1.2% below the high.

DexCom(DXCM) shares are trading with a volume of 591.06K, against a daily average of 4.61M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

DXCM News

TipRanks 1d

DexCom price target raised to $105 from $90 at RBC Capital

RBC Capital raised the firm’s price target on DexCom (DXCM) to $105 from $90 and keeps an Outperform rating on the shares as part of a broader research note pre...

Simply Wall St 3d

How Could DexCom Turn Type 2 CGM Gaps Into Growth?

DexCom (NasdaqGS:DXCM) released its global "State of Type 2 Report" at EASD 2026, focusing on Type 2 diabetes care and CGM use. The report highlights gaps in a...

Analyst ratings

84%

of 31 ratings

Buy

83.9%

Hold

16.1%

Sell

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.